Tempus Ai, INC Form 4 insider transactions

Ryan Fukushima, CEO, Data of Tempus AI, Inc., reported a transaction in 62,239 shares of common stock on August 12, 2026.

Ryan Fukushima, CEO, Data of Tempus AI, Inc., sold 20,000 shares of common stock on August 7, 2026 for $50.04 per share.

Andrew Polovin, EVP, Chief Legal Officer of Tempus AI, Inc., received 40,000 shares of common stock on July 29, 2026.

James William Rogers, Chief Financial Officer of Tempus AI, Inc., received 40,000 shares of common stock on July 29, 2026.

Eric P Lefkofsky, CEO and Chairman, a Director and 10% owner of Tempus AI, Inc., sold 250,000 shares of common stock on July 28, 2026.

Tempus AI announced a definitive agreement to acquire Personalis for $1.5 billion, aiming to enhance its oncology diagnostics and biopharma offerings.

Tempus AI announced its agreement to acquire Personalis, Inc., aiming to integrate genomic data and AI-driven insights.

Tempus AI announced its agreement to acquire Personalis, Inc. for $1.7 billion, aiming to integrate Personalis's ultrasensitive molecular residual disease (MRD) testing into its AI-enabled precision oncology platform.

Tempus AI, Inc. announced its entry into a definitive Agreement and Plan of Merger with Personalis, Inc., outlining the terms of a two-step merger transaction.

Tempus AI announced its definitive agreement to acquire Personalis, Inc. for $1.5 billion, aiming to integrate Personalis's minimal residual disease (MRD) technology into its AI-enabled precision oncology platform.

Ryan Fukushima, CEO, Data at Tempus AI, Inc., reported the sale of Class A Common Stock valued at over $3.5 million, executed under a pre-arranged trading plan.

Ryan Fukushima, CEO of Data at Tempus AI, Inc., reported a transaction involving Class A Common Stock under a Rule 10b5-1 trading plan.

Eric Lefkofsky, CEO and Chairman of Tempus AI, Inc., reported transactions involving the sale of Class A Common Stock.

Director Jennifer Doudna executed a Rule 10b5-1 plan transaction involving Tempus AI, Inc. Class A Common Stock.

Tempus AI, Inc. Chief Financial Officer, James William Rogers, reported a sale of 11,529 shares of Class A Common Stock on June 25, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

David R. Epstein, a Director at Tempus AI, Inc., reported a transaction involving Class A Common Stock on June 1, 2026, executed under a Rule 10b5-1 trading plan.

CEO and Chairman Eric Lefkofsky sold 166,250 shares of Tempus AI Class A Common Stock via a pre-arranged 10b5-1 trading plan.

Tempus AI director Eric Belcher received 5,913 restricted stock units as part of his compensation package, vesting in May 2027.

Tempus AI, Inc. director Nadja West has been granted 5,913 restricted stock units as part of her compensation, increasing her total holdings to 37,981 shares.

Director Theodore Leonsis received 5,913 restricted stock units, increasing his total beneficial ownership to over 88,000 shares.

Tempus AI Director Scott Gottlieb was awarded 5,913 restricted stock units as part of his compensation, increasing his total holdings to over 40,000 shares.

Director Wayne A.I. Frederick received a grant of 5,913 restricted stock units as part of his compensation, increasing his total holdings to 30,749 shares.

Tempus AI director David R. Epstein received a grant of 5,913 restricted stock units, increasing his total beneficial ownership to 31,714 shares.

Director Jennifer A. Doudna was awarded 5,913 restricted stock units as part of her compensation, increasing her total holdings in the company.

Director Peter J. Barris received a grant of 5,913 restricted stock units as part of his compensation, increasing his total holdings in Tempus AI.

Tempus AI's CEO of Diagnostics, Thomas Edward Schoenherr, sold 1,580 shares of Class A Common Stock to cover statutory tax withholding obligations.

Tempus AI's Chief Financial Officer, James William Rogers, sold 10,853 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Chief Legal Officer Andrew Polovin sold 8,703 shares of Tempus AI to satisfy tax withholding requirements following the vesting of restricted stock units.

CEO Ryan Fukushima transferred 162,239 shares of Tempus AI Class A Common Stock as a bona fide gift.

Tempus AI, Inc. CEO Thomas Schoenherr acquired 13,642 shares of Class A Common Stock through restricted stock units.